130 related articles for article (PubMed ID: 3265237)
21. Chromatographic purification and properties of a therapeutic human protein C concentrate.
Radosevich M; Zhou FL; Huart JJ; Burnouf T
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jun; 790(1-2):199-207. PubMed ID: 12767332
[TBL] [Abstract][Full Text] [Related]
22. The separation of clotting factors II (prothrombin) and IX (plasma thromboplastin component) by isoelectric focusing.
Pechet L; Smith JA
Biochim Biophys Acta; 1970 Mar; 200(3):475-85. PubMed ID: 4985341
[No Abstract] [Full Text] [Related]
23. Development of large-scale fractionation methods. II. Isolation of a factor IX concentrate (prothrombin complex) for clinical use.
Wickerhauser M; Sgouris JT
Vox Sang; 1972; 22(2):137-60. PubMed ID: 5013242
[No Abstract] [Full Text] [Related]
24. Preparation and properties of a therapeutic factor IX concentrate.
Suomela H; Myllylä G; Raaska E
Vox Sang; 1977 Jul; 33(1):37-50. PubMed ID: 883244
[TBL] [Abstract][Full Text] [Related]
25. Large-scale preparation of thrombin from human plasma.
Aizawa P; Winge S; Karlsson G
Thromb Res; 2008; 122(4):560-7. PubMed ID: 18329699
[TBL] [Abstract][Full Text] [Related]
26. In vitro thrombogenicity tests of factor IX concentrates. II: effects of phospholipids and heparin.
Prowse CV; Boffa MC; Guthrie C; Pepper DS
Thromb Haemost; 1980 Feb; 42(5):1368-77. PubMed ID: 7368144
[TBL] [Abstract][Full Text] [Related]
27. [Preparation of factor IX concentrate with the use of DEAE-cellulose and its therapeutic results].
Uszyński L; Poszwiński P
Acta Haematol Pol; 1971; 2(2):109-14. PubMed ID: 5170671
[No Abstract] [Full Text] [Related]
28. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
Thomas DP; Hampton KK; Dasani H; Lee CA; Giangrande PL; Harman C; Lee ML; Preston FE
Br J Haematol; 1994 Aug; 87(4):782-8. PubMed ID: 7986719
[TBL] [Abstract][Full Text] [Related]
29. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
Sultan Y; Boyeldieu D; Stieltjes N
Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
[TBL] [Abstract][Full Text] [Related]
30. Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives.
Edwards CA; Piet MP; Chin S; Horowitz B
Vox Sang; 1987; 52(1-2):53-9. PubMed ID: 3111089
[TBL] [Abstract][Full Text] [Related]
31. In vitro characterization of various heat-treated prothrombin complex concentrates (PCC).
Yoshioka A; Nakagawa O; Uehara Y; Sakai T; Sugimoto M; Takamiya O; Tanaka I; Fukui H
Thromb Res; 1987 Aug; 47(4):449-58. PubMed ID: 2958958
[TBL] [Abstract][Full Text] [Related]
32. The preparation and clinical use of a new concentrate containing factor IX, prothrombin and factor X and of a separate concentrate containing factor VII.
Dike GW; Bidwell E; Rizza CR
Br J Haematol; 1972 Apr; 22(4):469-90. PubMed ID: 4112845
[No Abstract] [Full Text] [Related]
33. Preparation and properties of a therapeutic inter-alpha-trypsin inhibitor concentrate from human plasma.
Michalski C; Piva F; Balduyck M; Mizon C; Burnouf T; Huart JJ; Mizon J
Vox Sang; 1994; 67(4):329-36. PubMed ID: 7535497
[TBL] [Abstract][Full Text] [Related]
34. A therapeutic concentrate of coagulation factors II, IX and X from citrated, factor VIII-depleted plasma.
Middleton SM; Bennett IH; Smith JK
Vox Sang; 1973 May; 24(5):441-56. PubMed ID: 4691239
[No Abstract] [Full Text] [Related]
35. Biochemical and physical properties of a solvent-detergent-treated fibrin glue.
Burnouf-Radosevich M; Burnouf T; Huart JJ
Vox Sang; 1990; 58(2):77-84. PubMed ID: 2160146
[TBL] [Abstract][Full Text] [Related]
36. Prothrombin complex concentrates: preparation, properties, and clinical uses.
White GC; Lundblad RL; Kingdon HS
Curr Top Hematol; 1979; 2():203-44. PubMed ID: 318075
[No Abstract] [Full Text] [Related]
37. [Isolation of factor IX concentrate from cryosupernatant of donor's plasma].
Fetisova LV; Viazova EP; Khametova RN; Shuvalova AL; Azhigirova MA; Lazarev VA; Zeĭnalov AM
Gematol Transfuziol; 1991 Jun; 36(6):34-6. PubMed ID: 1769497
[TBL] [Abstract][Full Text] [Related]
38. Purification of blood coagulation factors II, VII, IX and X from bovine citrated plasma.
Reekers P; Hemker HC
Haemostasis; 1972; 1(1):2-22. PubMed ID: 4668761
[No Abstract] [Full Text] [Related]
39. The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation.
Piët MP; Chin S; Prince AM; Brotman B; Cundell AM; Horowitz B
Transfusion; 1990 Sep; 30(7):591-8. PubMed ID: 2402772
[TBL] [Abstract][Full Text] [Related]
40. Activated factor IX-antithrombin III complexes in human blood: quantification by an enzyme-linked differential antibody immunoassay and determination of the in vivo half-life.
Takahashi I; Kato K; Sugiura I; Takamatsu J; Kamiya T; Saito H
J Lab Clin Med; 1991 Oct; 118(4):317-25. PubMed ID: 1940573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
